AngioDynamics' VenaCure EVLT™ Varicose Vein Treatment Featured By FOX News

January 25, 2010 at 12:00 AM EST
AngioDynamics' VenaCure EVLT&#8482 Varicose Vein Treatment Featured By FOX News

QUEENSBURY, N.Y. January 25, 2010 - AngioDynamics (NASDAQ: ANGO) today highlighted coverage of its VenaCure EVLT treatment for varicose veins on FOX affiliates across the United States. The television segment can be accessed online at the web address

In the feature, FOX News Channel Senior Medical Contributor Dr. Manny Alvarez discussed the surprising number of men in the United States who suffer from varicose veins, a condition more commonly associated with women.

"Although women have a higher risk of developing varicose veins, more than 25 percent of men in the United States are plagued by them," said Dr. Alvarez during the segment. "People think they only occur in women and elderly women, and that they're cosmetic, when in fact it can happen in very young people, men as well, and it's often a medical problem."

Dr. Alvarez profiled 41-year-old firefighter Brian Pericone and his treatment by Dr. Gina Louie with the VenaCure EVLT system. Dr. Louie's New Jersey-based practice, Advanced Vascular Solutions, can be found online at

Dr. Alvarez said that previously the standard treatment for varicose veins was a procedure often called vein stripping "which is not very successful or very pleasant," he said. "But now, technology is changing all that," Dr. Alvarez said.

"The trend in modern medicine is toward the more minimally invasive as possible," said Dr. Louie. "I use a VenaCure EVLT system, it shortens the treatment considerably, it's much easier for the patient, it's done as an outpatient [procedure], and I use local anesthesia."

A recent review of clinical studies published in the Journal of Vascular Surgery found the estimated success rate of treating varicose veins - after three years - was 94 percent for laser ablation such as the AngioDynamics' VenaCure EVLT system, 84 percent for radiofrequency ablation, 78 percent for vein stripping and 77 percent for sclerotherapy.

For more information on the VenaCure EVLT system, visit and for more on AngioDynamics visit

About VenaCure EVLT Laser Vein Treatment

The VenaCure EVLT system uses targeted laser energy to seal a varicose vein shut, providing treatment in less than an hour in the doctor's office with a high success rate and near immediate relief of symptoms as well as a return to normal activity immediately - with little or no pain. No general anesthesia or hospitalization and minimal-to-no scarring occurs. It is typically covered by insurance.

A patient receiving a VenaCure EVLT procedure can expect a doctor to use ultrasound to map out the vein. Local anesthetic is then applied. A thin laser fiber is inserted through a tiny entry point, usually near the knee. Laser energy is delivered to seal the faulty vein. Walking immediately after the procedure is encouraged. Normal daily activity can be resumed; but rigorous activities such as gym workouts are discouraged. There may be minor soreness and bruising. Any discomfort can be treated with over-the-counter, non-aspirin pain relievers as necessary.

About AngioDynamics

AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "potential," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company's expectations. Factors that may affect the actual results achieved by the Company include, without limitation, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, results of pending litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of the Company to execute its leadership development plan and integrate purchased businesses, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2009. The Company does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Company Contact:
AngioDynamics, Inc.
D. Joseph Gersuk, CFO
(800) 772-6446 x1608

Investor Relations Contacts:
EVC Group, Inc.
Doug Sherk/Jenifer Kirtland
(415) 896-2005

Media Contact:
EVC Group, Inc.
Chris Gale/ Steve DiMattia
(646) 201-5431